These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 18006217

  • 1. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
    Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ.
    Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
    [Abstract] [Full Text] [Related]

  • 2. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
    Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, Rittmaster RS.
    Prostate; 2005 May 15; 63(3):231-9. PubMed ID: 15538746
    [Abstract] [Full Text] [Related]

  • 3. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
    Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, Thompson IM, Troyer DA, Rittmaster RS, Lazier CB.
    J Urol; 2003 Nov 15; 170(5):2019-25. PubMed ID: 14532845
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN, Schröder FH.
    BJU Int; 2009 Nov 15; 104(9):1191-7. PubMed ID: 19624596
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 15; 22(2):389-402. PubMed ID: 18471794
    [Abstract] [Full Text] [Related]

  • 8. 5alpha-reductase isoenzymes 1 and 2 in the rat testis during postnatal development.
    Killian J, Pratis K, Clifton RJ, Stanton PG, Robertson DM, O'Donnell L.
    Biol Reprod; 2003 May 15; 68(5):1711-8. PubMed ID: 12606426
    [Abstract] [Full Text] [Related]

  • 9. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.
    Prostate; 2004 Feb 01; 58(2):130-44. PubMed ID: 14716738
    [Abstract] [Full Text] [Related]

  • 10. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M, Fleshner NE, Finelli A, Zlotta AR.
    Expert Rev Anticancer Ther; 2008 Jul 01; 8(7):1073-9. PubMed ID: 18588452
    [Abstract] [Full Text] [Related]

  • 11. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C, Gravina GL, Muzi P, Pomante R, Angelucci A, Vicentini C, Bologna M.
    J Urol; 2008 Jul 01; 180(1):367-72. PubMed ID: 18499161
    [Abstract] [Full Text] [Related]

  • 12. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS.
    Urology; 2004 Sep 01; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [Abstract] [Full Text] [Related]

  • 13. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
    Gleave M, Qian J, Andreou C, Pommerville P, Chin J, Casey R, Steinhoff G, Fleshner N, Bostwick D, Thomas L, Rittmaster R.
    Prostate; 2006 Nov 01; 66(15):1674-85. PubMed ID: 16927304
    [Abstract] [Full Text] [Related]

  • 14. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R.
    Urology; 2008 Oct 01; 72(4):808-12. PubMed ID: 18718641
    [Abstract] [Full Text] [Related]

  • 15. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS.
    J Urol; 1999 Jan 01; 161(1):332-7. PubMed ID: 10037433
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.
    Titus MA, Gregory CW, Ford OH, Schell MJ, Maygarden SJ, Mohler JL.
    Clin Cancer Res; 2005 Jun 15; 11(12):4365-71. PubMed ID: 15958619
    [Abstract] [Full Text] [Related]

  • 18. Overview of pivotal studies for prostate cancer risk reduction, past and present.
    Andriole GL.
    Urology; 2009 May 15; 73(5 Suppl):S36-43. PubMed ID: 19375625
    [Abstract] [Full Text] [Related]

  • 19. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct 15; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.